ByHeart promised to make a better infant formula, touting higher standards than its competitors. Now a botulism crisis is unfolding. https://t.co/OUo9RDrD3x ...

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) for violations of the federal securities laws on behalf of investors who purchased or acquired Perrigo securities between February 27, 2023 and November 4, 2025, inclusive (the “Class Period”). On November 17, 2025, a complaint was filed against the Compan ...

Biotech M&A Activity - Merck announced the acquisition of Cidara Therapeutics for approximately $9.2 billion, primarily for its antiviral drug aimed at preventing flu infections in high-risk patients, currently in late-stage clinical trials [1] - This acquisition follows Merck's earlier $10 billion deal to acquire Verona Pharma for respiratory drugs, indicating a trend of significant investments in biotech [1] - The dollar volume of M&A in the biotech sector reached $129 billion through October 31, 2025, a 43% increase compared to all of 2024, despite a 26% decrease in the number of deals, highlighting a shift towards larger, market-ready assets [3] Recursion's Challenges - Recursion has not successfully brought any drugs to market since its founding, with its shares dropping 86% since its IPO in April 2021, resulting in a current market cap of $2.2 billion [4] - The company reported a revenue decline of one-third to $44 million from $65 million over the last 12 months, while losses surged nearly 90% to $716 million [4] - Incoming CEO Najat Khan aims to tackle the challenges of AI in drug development, acknowledging the high failure rate in the industry [5] Infant Formula Outbreak - A botulism outbreak linked to ByHeart's organic infant formula affected 23 babies across 13 states, leading to multiple hospitalizations and five lawsuits from parents [6] - ByHeart had previously shut down its Pennsylvania manufacturing plant due to safety violations and announced a nationwide recall of its infant formula [7] Profluent's AI Innovations - Profluent, a startup focused on using AI for protein design, raised $106 million in new venture funding, bringing its total investment to $150 million and approaching a valuation of $1 billion [12] - The company aims to revolutionize drug development and agriculture by making biology programmable, which could lead to significant breakthroughs in therapeutics and diagnostics [11]

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Perrigo Company plc, alleging misrepresentations related to its infant formula business acquired from Nestlé, affecting investors who purchased securities between February 27, 2023, and November 4, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Perrigo securities during the specified period [1]. - Defendants are accused of making false statements regarding the infant formula business [2]. - Investors interested in participating as lead plaintiffs must file by January 16, 2026 [3]. Group 2: Legal Representation - Bernstein Liebhard LLP has a history of recovering over $3.5 billion for clients and has represented large public and private pension funds [4]. - The firm operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [3].

NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Skye Bioscience, Inc. (NASDAQ:SKYE) and Perrigo Company plc (NYSE:PRGO). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Skye Bioscience, Inc. (NASDAQ:SKYE) Class Period: November ...

Core Points - A shareholder has filed a securities class action lawsuit on behalf of investors who purchased or acquired securities of Perrigo Company plc between February 27, 2023, and November 4, 2025 [1] - The lawsuit alleges that the defendants made misrepresentations regarding Perrigo's infant formula business acquired from Nestlé [2] Legal Proceedings - Interested parties wishing to serve as lead plaintiff must file papers by January 16, 2026 [3] - Serving as lead plaintiff is not a requirement for sharing in any recovery, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [3] Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large public and private pension funds [4] - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4]

Attention parents. An entire line of organic baby formula is being recalled due to serious health risks. Byheart, a manufacturer of the formula you see right here on your screen, has recalled all of its products sold nationwide.This after at least 15 babies have become sick from an outbreak of infant bachelism, which experts warn can cause paralysis in kids under one. NBC News health reporter Arya Bendix is following this all for us. Arya, we're talking about, you know, itty bitty babies here.We know that a ...

US regulators are urging parents to stop using all ByHeart infant formula products after more than a dozen babies became seriously ill, setting off a recall of all the company’s products https://t.co/xNAVj77dGG ...

Core Viewpoint - Perrigo Company plc is initiating a strategic review of its infant formula business to assess various alternatives and align with its 'Three-S' plan, focusing on disciplined capital allocation and improving returns [1][2][4] Business Overview - The infant formula business is projected to generate net sales of approximately $360 million in 2025, representing about 90% of Perrigo's global Nutrition category and less than 10% of the company's total annual net sales [3] - The operations have stabilized, producing quality assured formula, and Perrigo remains the only large-scale U.S. store brand and contract manufacturer with a significant near-term innovation pipeline [3] Strategic Intent - The review aims to accelerate cash flows and reassess a previously announced investment of $240 million in the infant formula business while optimizing portfolio impact [2] - The CEO emphasized the need for discipline in positioning the company's portfolio for sustainable growth and free cash flow generation, noting that the external environment has changed, affecting the strategic fit with consumer health OTC businesses [4]

What did you learn from Airbnb, your experience at Airbnb that helped you take on this challenge. Well, I'm not an scientist, so I went into this eyes wide open going, I will need to bring on the team and the group of experts to be able to build the formulation to navigate the regulations. But what I did take was just an ounce of that courage to disrupt something that was the status quo.And remember, Airbnb was going up against the hospitality industry. It was questioning how people should travel in ways th ...